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Background: Although there is no strong evidence of benefit, chest physiotherapy (CP) seems
to be commonly used in simple pneumonia. CP requires equipment and frequently involves the
assistance of a respiratory therapist, engendering a significant medical workload and cost.
Aim: To measure and compare the efficacy of two modalities of chest physiotherapy (CP)
guideline implementation on the appropriateness of CP prescription among patients
hospitalised for community-acquired pneumonia (CAP).
Patients and methods: Wemeasured the CP prescription rate and duration in all consecutive CAP
inpatients admitted in a division of general internalmedicine at an urban teaching community hos-
pital during three consecutive one-year time periods: (1) before any guideline implementation;
(2) after a passive implementation by medical grand rounds and guideline diffusion through mail-
ing; (3) after adding a one-page reminder in the CAP patient’s medical chart highlighting our rec-
ommendations. Death and recurrent hospitalisation rates within one year after hospitalisation
were recorded to assess whether CP prescription reduction, if any, impaired patient outcomes.
Results: During the three successive phases, 127, 157, and 147 patients with similar characteris-
tics were included. Among all CAP inpatients, the CP prescription rate decreased from 68%y; COPD, chronic obstructive pulmonary disease; PSI, pneumonia severity index; CAP, community-
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1258 I. Guessous et al.(86/127) to 51% (80/157), and to 48% (71/147), respectively (P for trend <0.01 for trend). A
significant reduction in CP duration was observed after the active guideline implementation
(12.0, 11.0, 7.0 days, respectively) and persisted after adjustment for length of stay. Reductions
in CP prescription rate and duration were also observed among CAP patients with COPD CP
prescription rate: 97% (30/31), 67% (24/36), 75% (35/47), respectively (P < 0.01 for trend).
The mean cost of CP per patient was reduced by 56%, from $709 to $ 481, and to $309, respec-
tively. Neither the in-hospital deaths, the one-year overall recurrent hospitalisation nor
the one-year CAP-specific recurrent hospitalisation significantly differed between the three
phases.
Conclusion: Both passive and active implementation of guidelines appear to improve the
appropriateness of CP prescription among inpatients with CAP without impairing their
outcomes. Restricting CP use to patients who benefit from this treatment might be an
opportunity to decrease CAP medical cost and workload.
ª 2008 Elsevier Ltd. All rights reserved.GUIDELINE INPATIENTS WITH CAP
Chest physiotherapy prescription recommendations:
1) Indications
• Severe pulmonary pathology (COPD)
• Neuromuscular pathology
• Important bronchial secretions
2)  Duration
• Revaluate the prescription every 3 days
Figure 1 Guideline recommendations.Introduction
Community-acquired pneumonia (CAP) is a frequent disease
often leading to hospitalisation. In community studies, the
annual incidence of CAP ranges from 4 to 12 per 1000 adults
per year and increases with age.1e3 It is estimated that
more than 5 million cases of CAP occur annually in the
United States.4 Hospitalisation is required for 15e42% of
patients with CAP and accounts for about 90% of the total
annual cost of CAP,5,6 which is estimated at $8.4 billion in
the United States.4 Therefore, interventions likely to
reduce the medical cost of CAP have been proposed.7
The rationale of certain CAP therapies has been
questioned. One of them concerns the prescription of chest
physiotherapy (CP). Although new techniques for airway
clearance have emerged these last decades, the rare
evidence for their benefit is weak.8 Reviews and meta-
analyses on the efficacy of CP mainly concern patients
suffering from cystic fibrosis.9e14 There is no strong
evidence to support the use of CP in simple (uncompli-
cated) pneumonia (i.e., pneumonia without pleural
effusion, empyema, lung abscess, necrotising pneumonias,
pneumothorax, or ICU status).15,16 Moreover, there is very
little data regarding the proportion of CAP inpatients
receiving CP prescription. Among the existing data, CP
seems clearly overused.15,17,18 We aimed to measure and
compare the efficacy of two modalities of CP guideline
implementation on the appropriateness of CP prescription.
Patients and methods
Study protocol
An evidence-based guideline for the management of
inpatients with CAP was developed at our institution. This
clinical guideline was developed by a panel including
a hospital practitioner, infectiologist, pneumologist,
clinical microbiologist, and clinical epidemiologist working
at our institution and was reviewed, commented on and
approved by three external experts. Experts in charge of
each topic have searched and critically appraised published
guidelines and studies identified in a literature search. A
hierarchical evaluation of the strength of evidence wasapplied for each recommendation. The guidelines were
published in the official journal of the Swiss Society of
Internal Medicine.19 The guidelines referred to the manage-
ment of adult CAP of all ages in the community or in hospi-
tal. They contained recommendations on CAP diagnosis
(e.g., general and microbiological investigations), severity
assessment (e.g., prognostic score), management (e.g.,
antibiotic choice), and prevention (e.g., pneumococcal
vaccination). The panel determined that patients with
conditions leading to mucostasisddue to hypersecretion
of mucus or to decreased ability to clear secretionsdwere
at increased risk of recurrent bronchial infections. Accord-
ingly, the guidelines recommended: (1) to reserve CP
prescription for patients with severe pulmonary pathology
(COPD), neuromuscular pathology, and important bronchial
secretions and (2) to revaluate the prescription every
3 days (Fig. 1).
Chest physiotherapy prescription rate
and duration
CP prescription rate and duration were measured in all
consecutive CAP inpatients admitted during three consecu-
tive one-year time periods: (1) before any guideline
implementation (phase I, i.e., baseline); (2) after a passive
implementation by medical grand rounds and guideline
diffusion through mailing (phase II: passive implementation);
Appropriateness of chest physiotherapy prescription 1259(3) after adding, on the day of patient admission, a one-page
reminder in the CAP patient’s medical chart highlighting our
recommendations (phase III: active implementation) (Fig. 2).
The CAP guideline was developed at the end of phase I so that
it would not affect the clinical management of patients in-
cluded in phase I.
CP sessions in CAP varied from case to case, but
generally consisted of positioning the patient to optimise
ventilation and perfusion, external vibration, and incentive
spirometry. The total cost of CP for each phase was
calculated based on a cost estimation of $90.90 per day
of CP, which included one intensive session and one soft CP
session. In addition, in-hospital mortality and recurrent
hospitalisation rates within one year after hospitalisation
were recorded to assess whether CP prescription reduction,
if any, impaired patient outcomes.
Patients and data
This study was conducted from 1997 to 2001 in the Service
of Internal Medicine at the University Hospital Centre in
Lausanne, Switzerland, a 900-bed teaching hospital serving
as a city hospital and tertiary reference centre providing
services to an area with more than 300,000 inhabitants. All
consecutive adult patients (age 18 years) hospitalised
with a primary diagnosis of CAP were eligible for the study.
Records of phases I and II (retrospective data) were
identified through a sensitive review of ICD-9-CM diagnostic
discharge codes including pneumonia with or without
identified pathogens. Records of phase III (prospective
data) were identified daily in the emergency room by
a research study nurse and by the fellow in charge of the
study. All adult patients hospitalised with a primary diagno-
sis of CAP were eligible for the study. The inclusion criteria
were the following: age 18 years; acute onset of at least
one clinical finding suggestive of pneumonia, including
cough, dyspnoea, pleuritic chest pain, sputum production,
fever or altered mental status; and the presence of
a newly-acquired radiographic pulmonary infiltrate
confirmed by a radiologist. Patients with immunodeficiency
virus infection, neutropenia related to chemotherapy,
organ transplant, cystic fibrosis or congestive heart failure
were excluded, as were patients who were transferred to
the ICU, admitted from a nursing home, hospitalised within
the 10 previous days or discharged home during the first
24 h of hospitalisation. For patients hospitalised with CAP
on more than one occasion during the study period, only
the initial episode was evaluated.
Data on demographic characteristics, comorbid illnesses,
physical examination findings, initial investigations, anti-
biotherapy, ancillary treatments, follow-up and outcomeNo intervention
Guideline diffu
through medical 
rounds/ intern
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Figure 2 Phases ofwere collected by chart review. Severity of community-
acquired pneumonia was assessed by the pneumonia
severity index (PSI) proposed by Fine et al.20 The PSI is
based on derivation and validation cohorts of more than
50,000 patients with CAP. Briefly, the PSI stratifies patients
into 5 mortality risk classes, and its ability to predict mortal-
ity has been confirmed in multiple subsequent studies. On
the basis of associatedmortality rates, it has been suggested
that risk class I and II patients should be treated as
outpatients, risk class III patients should be treated in an
observation unit or with a short hospitalisation, and risk class
IV and V patients should be treated as inpatients. A diagnosis
of COPD was retained on the basis of ICD-9-CM diagnostic
discharge codes. Medical records of all included patients
were manually and electronically reviewed using hospital
databases to assess the number, date and cause of
re-admissions.
Statistical analysis
Descriptive and comparative statistical tests (paired and
non-paired t-test, Chi square test or exact Fisher test), and
P for linear trend to examine trends across phases were
applied using Stata (V 9.1, Stata Corporation, College
Station, TX, USA). P values <0.05 were considered signifi-
cant. The inflation effect on hospital charges were adjusted
using the Bureau of Labor Statistic’s Consumer Price Index
(http://www.bls.gov/cpi/). Data are given as percentage
or mean  standard deviation (SD).
Results
Patients
During the three successive phases, 127, 157 and 147
patients were included, respectively. Patients in the three
groups were similar in age, gender, severe CAP according to
the pneumonia severity index, and COPD diagnosis. They
slightly but significantly differed in admission PaO2,
with phase I patients being more frequently hypoxemic
(Table 1).
Effect of intervention
The number of CP prescriptions was significantly lower
during phases II and III compared to phase I (Fig. 3). Among
all CAP inpatients, the CP prescription rate decreased from
68% (86/127), to 51% (80/157) and to 48% (71/147), in phase
I, II and III, respectively (P for trend <0.01). The rate of CP
prescription also significantly decreased among CAPsion
grand
et
One-page reminder
inpatient medical chart
24 36 months
n
Phase III
Passive + Active implementation
implementation.
Table 1 Patient characteristics at time of hospital admissiona
Characteristics Phase I: baseline
(nZ 127)
Phase II: passive
implementation (nZ 157)
Phase III: passive þ active
implementation (nZ 147)
P value
for trend
Age, yearsb 71 (16) 71 (17) 71 (18) 0.9
Male 58 59 61 0.8
COPD 24 23 31 0.2
PSI IV/V 61 64 59 0.7
Respiratory rate >30/min 16 17 14 0.7
PaO2 <60 mmHg 43 28 34 0.04
COPD, chronic obstructive pulmonary disease; PSI, pneumonia severity index.
a Data are given as percentage of each group unless otherwise indicated.
b Data are given as mean (standard deviation).
1260 I. Guessous et al.inpatients without COPD from 58% (59/96), to 46% (56/121),
and to 36% (36/100) (P for trend <0.01). The rate of
prescription also decreased for CAP inpatients with COPD
from 97% (30/31) in phase I to 67% (24/36) in phase II and
75% (35/47) in phase III (P for trend <0.01).
Fig. 4 shows that the reduction in CP duration was par-
ticularly impressive after active guideline implementation,
decreasing from 12.0 (SD 7.3), to 11.0 (SD 5.6) and to 7.0
(SD 3.9) days, respectively (P for trend <0.01). The dura-
tion of CP prescription also significantly decreased after
the active guideline implementation among CAP inpatients
without COPD [11.2 (SD 7.2), 10.1 (SD 7.7), 6.9 (SD 4.5), (P
for trend <0.01)] and CAP inpatients with COPD [12.2 (SD
6.7), 11.2 (SD 6.8), 7.2 (SD 4.3), (P for trend <0.01)].
As the length of hospital stay decreased during the three
phases (median length of stay: 9.0, 8.0, and 7.5 days,
respectively), a correlation between the CP’s length of
prescription and the length of CAP inpatient hospital stay
was measured. These correlations decreased considerably
after the two modalities of guideline implementations,
from a strong correlation (r2Z 0.78 in phase I) to a weak
correlation (r2Z 0.55 in phase II and r2Z 0.24 in phase
III) after active guideline implementation. Moreover, the
CP prescription, when judged necessary, was significantly
limited to the beginning of the hospital stay. To better
evaluate the mean number of days of CP prescription per
patient, we calculated the index of prescription (totalFigure 3 Chest physiotherapy prescription rate by phases. Phase
trend <.01day of prescription divided by total number of patients).
The index of prescription significantly decreased between
the three phases with greater reduction in phase III.
Indeed, the index of prescription decreased from 7.8 to
5.3, and to 3.4 in phases I, II and III, respectively (P for
trend <0.01). The total cost of CP decreased from
$90,101 (2001 inflation-adjusted $97,895) to $75,654
(2001 inflation-adjusted $80.422) and to $45,460 (2001
inflation-adjusted $46,753) in phases I, II and III, respec-
tively (Fig. 5). The mean cost of CP per one patient
hospitalised in a general ward for CAP was reduced by
56%, from $709 (2001 inflation-adjusted $770) to $481
(2001 inflation-adjusted $512), and to $309 (2001 infla-
tion-adjusted $318) during phases I, II and III, respectively.
Secondary outcomes
In-hospital death rates among all patients remained low
and were similar between the three phases: 4.6%, 6.4%,
5.4%, respectively (P for trend 0.77). Neither the one-year
overall recurrent hospitalisation rate (27%, 22%, 28%,
PZ 0.65 for trend) nor the one-year CAP-specific
recurrent hospitalisation rate (25%, 37% and 36%, P for
trend 0.41) significantly differed between the three
phases. Additionally, the 3-month, 6-month and 9-month
rates of recurrent hospitalisations were similar between
the three phases (Table 2).I (nZ 127), phase II (nZ 157) and phase III (nZ 147). P for
Figure 4 Duration of chest physiotherapy by phases. Phase I (nZ 127), phase II (nZ 157) and phase III (nZ 147). P for
trend <.01
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Our study demonstrated that both passive and active
implementations of the guideline appeared to improve
the appropriateness of CP prescription among inpatients
with CAP. Improvement was more pronounced during the
active implementation phase with a greater impact on
chest physiotherapy duration. Moreover, the reduction in
CP prescription and duration seemed disconnected with
worse medical outcomes. The total cost of CP was reduced
by nearly 50% after the active implementation.
In recent years, strategies aimed at reducing the medical
workload and cost of patients hospitalised for CAP have been
proposed. Since a length of stay reduction has been generally
unassociatedwith an increase in adverse outcomes,21 efforts
have focused on interventions inclined to reduce the length
of stay for patients with CAP. Therefore, processes including
triage decisions, risk stratification for outpatient care and
early transition from intravenous to oral antibiotics have
been evaluated.19,22e24 in addition to the length of hospital
stay, CAP inpatient management includes practices not
supported by evidence of effectiveness.
Indications regarding CP prescription are clearly lacking
in CAP guidelines and review.25e27 The British ThoracicFigure 5 Index of prescription and cost of chest physiother-
apy by phases. Phase I (nZ 127), phase II (nZ 157) and phase
III (nZ 147).Society Guideline and European Study on Community Ac-
quired Pneumonia (ESOCPA) committee are among the
few that assessed recommendations regarding CP.28,29 CP
in acute pneumonia obtained a grade III recommendation
(i.e., one or more retrospective clinical studies that
address but do not rigorously answer the question) in the
British Thoracic Society Guideline, and the ESOCAP commit-
tee stressed that the body of data regarding CP is small but
that CP seemed justified for patients with chronic airway
disease.
Despite the lack of evidence, CP seems to be overused.
In 1996, Alexander et al. demonstrated that more than 50%
of CP prescriptions were inappropriate.15 This high level of
inappropriateness was previously observed.17,30,31 More
recently, we reported that 59% of inpatients with CAP
received CP although they had no accepted indications.18
Not only has CP been overprescribed, CP prescription
duration appeared to be too long, with duration quite
similar to the length of hospital stay.18 One explanation
might be that physicians do not regularly reassess the
rationale for pursuing CP.
CP requires equipment and frequently involves the
assistance of at least one respiratory therapist, engender-
ing a significant medical workload and cost. When including
the personnel and equipment costs, the annual cost of CP
delivered in a medical centre has been estimated to be
more than $1 million.15
Strategies to reduce the inappropriate utilisation of CP
have been evaluated through randomised and prospective
observational studies. One of them showed that the number
of inappropriate CP prescriptions could be significantly
reduced without impairing the patient’s outcome. It was
also estimated that the reduction would be associated with
annual cost savings of $319,000.15 More recently, three ad-
ditional studies have investigated different strategies to
improve respiratory care utilisation.16,32,33 All compared
the impact of respiratory therapist-initiated treatment to
physician-directed orders on CP prescription rate. These
three studies suggested that the instances of inappropriate
respiratory care significantly decrease with respiratory
therapist-initiated treatment.
Our study has some limitations. First, we have not
clearly defined the three CAP indications, i.e., a ‘‘severe
Table 2 Rate and cause of recurrent hospitalisationa
Number of months
after hospitalisation
Phase I: baseline
(nZ 127)
Phase II: passive
implementation (nZ 157)
Phase III: passive þ active
implementation (nZ 147)
P value
for trend
CAP (%) Other (%) CAP (%) Other (%) CAP (%) Other (%)
0e3 4 (3.1) 13 (10.2) 8 (5.0) 9 (5.7) 7 (4.7) 6 (4.0) 0.1
4e6 2 (1.5) 4 (3.1) 1 (0.6) 5 (3.1) 2 (1.3) 8 (5.4) 0.7
7e9 1 (0.7) 4 (3.1) 4 (2.5) 6 (3.8) 3 (2.0) 10 (6.8) 0.6
10e12 2 (1.5) 5 (3.9) 0 (0.0) 2 (1.2) 3 (2.0) 3 (2.0) 0.4
Overall 9 (7.0) 26 (20.0) 13 (8.2) 22 (14.0) 15 (10.2) 27 (18.3) 0.6
CAP, community-acquired pneumonia.
a Data are given as number (percentage).
1262 I. Guessous et al.COPD,’’ ‘‘neuromuscular pathology,’’ or ‘‘important bron-
chial secretions,’’ which might limit the generalisation of
our findings. Second, the ‘‘before and after study’’ design
might have introduced bias in the following manner.
Differences in confounding factors between the three
groups might partially explain differences in outcome for
reasons unrelated to the CAP guidelines. For example, the
lower proportion of hypoxemic patients at admission could
have resulted in a decrease in CP prescriptions in groups
with less hypoxemic patients. Third, because the physicians
who worked in our institution during phases II and III might
have been informed of the study aims, they might have
changed their practice independently of the guideline
implementation (Hawthorne effect). Finally, our guideline
reported weak evidence for prescribing CP in CAP. Although
guidelines are generally understood as a compression of
strong indications aimed to correct the inappropriate
underuse of an intervention, we stress that the clinical
utility of guidelines should not be limited to this aim.
Indeed, the inappropriate overuse of medical interventions
has also stimulated the development of recommendations,
and guidelines with a limited amount or lack of evidence,
appeared to also help doctors in making the right decisions,
i.e., not to prescribe.34e39 Although we cannot report the
exact mechanism by which providers did eventually decide
not to prescribe CP and acknowledge that further work
should be done to assess the impact of the level of evidence
(i.e., weak) on provider decision, we demonstrated the
initial step, that is the reduction of unnecessary CP
prescription after guideline implementation. We do think
that our findings might add new elements to the experi-
ences assessed from previous studies. First, the method
we used to implement our guideline e a one-page reminder
in CAP patients’ medical charts e might be easier to
reproduce (external validity) and less expensive than
strategies previously proposed. For example, Alexander
et al. chose to put a physician fellow in charge of explaining
by phone to each physician whether CP is indicated for their
patients.15 This strategy seems hardly reproducible, as it
requires an additional physician, and probably inefficient
because of its potential cost. Second, previous studies
chose a respiratory therapist-initiated treatment approach
(i.e., respiratory therapists were first specifically trained to
use algorithms and then ordered or not CP to inpa-
tients).16,32,33 Although these studies showed significant
reduction in respiratory care services, their conclusions
might be difficult to generalise in other settings withlimited training resources and respiratory therapists. Asking
respiratory therapists to evaluate each inpatient and
decide whether they should receive CP could further
increase their workload and limit their availability for other
patients who may require urgent respiratory care. By using
medical rounds or a one-page reminder in a patient’s med-
ical chart, our strategy was a physician-based approach
that might not only be more reproducible but also better
fulfil the final aims of guideline implementation, which
are to change and improve physicians’ clinical practice.
Finally, our study highlighted the need to further evaluate
whether CP is actually useful for inpatients with CAP. The
beforeeafter study is the most commonly encountered de-
sign in quality improvement research;40 however, to obtain
valid assessment of the efficacy of CP in CAP, more robust
designs (e.g., randomised controlled trials) are needed.
In summary, although it does not use a randomised
design, this study indicates that guidelines for the use of
CP in patients with CAP might enable more appropriate and
cost-saving care by restricting its use and limiting it for
absolutely necessary occasions. The external validity of this
simple intervention should be evaluated in other settings
and eventually at different levels of CAP medical care.
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